论文部分内容阅读
目的：评价格拉司琼预防化疗所致呕吐的效果和不良反应。方法：１１２ 例分成３ 组：１） 康泉自身对照组２１ 例；２） 胃复安自身对照组１０ 例；３）开放组８１ 例。格拉司琼或康泉３ｍｇ 化疗前静注，１ 天化疗方案当天用；３ 天或５ 天方案第１、３ 天用。胃复安２０ｍｇ 每次化疗前肌注。结果：第１ 组康泉和格拉司琼有效率均为９０ ．５ ％（ Ｐ＝ ０．５） ；第２ 组胃复安和格拉司琼有效率分别为７０％ 和１００ ％ ；第３ 组有效率为８８ ．９ ％ ；全组为９０．２ ％ （９５ ％ ＣＩ：８４ ．７ ％ ～９５ ．７ ％） 。不良反应中头晕８ ．９ ％（１０／１１２） 、头痛４．５％ （５／１１２）、腹部不适１１ ．６ ％ （１３／１１２） 和便秘１４ ．３ ％ （１６／１１２）。结论：格拉司琼是一安全、有效的５ － ＨＴ３ 受体拮抗剂止吐新药。
Objective: To evaluate the efficacy and adverse reactions of granisetron in preventing vomiting induced by chemotherapy. METHODS: One hundred and twenty-two patients were divided into 3 groups: 1) Kangquan self-control group, 21 cases; 2) Gastrician self-control group, 10 cases; 3) Open group, 81 cases. Granisetron or Kangquan 3mg intravenously before chemotherapy, 1 day chemotherapy regimen; 3 days or 5 days regimen on days 1 and 3 Metoclopramide 20 mg before each chemotherapy. Result: The first group Kangquan and granisetron had an effective rate of 90. 5 % (P = 0.5); Group 2 metoclopramide and granisetron effective rates were 70% and 100%, respectively; Group 3 efficacy rate was 88. 9 % ; The total group was 90.2 % (95 % CI : 84.7 % - 95.7 %). Dizziness in adverse reactions. 9 % (10/112), headache 4.5% (5/112), abdominal discomfort 11. 6 % (13/112) and constipation 14. 3% (16/112). CONCLUSION: Granisetron is a safe and effective antiemetic agent for 5-HT3 receptor antagonists.